Cracking the Circadian Code The most recent WEEKLY described the molecular basis of circadian rhythm, the internal 24-hour clock that governs many of our biological processes. Disrupting this cycle over the long term is linked to diseases including obesity, diabetes,...
The Science Behind the Deal Earlier this week, news of the $8.7 billion acquisition of gene therapy company AveXis (Bannockburn, IL) by Novartis (Basel, Switzerland) made big biotech headlines. AveXis’ lead candidate, AVXS-101, is now in Phase III clinical...
Coming Soon To A Supermarket Near You Coming soon to a supermarket near you: apples that have been genetically modified to resist browning. Dubbed Arctic Apples, the plants were approved two years ago by the USDA and will begin appearing on...
A Big Pain The opioid addiction crisis gained attention at the highest levels of U.S. policy circles this past year. Presidential candidates that disagreed on nearly everything else vowed to make fighting the epidemic a priority if elected. In July, the U.S. Senate...
Regulatory T-Cells Make A Pathway After our focus on T-cell activated immunotherapies revving up the immune response, we turn to the other side of the coin—a subset of helper T-cells known as regulatory T-cells. Regulatory T-cells (Tregs) suppress the immune response....
BIOPHARMA’S DARLING Immunotherapy is the current biopharma darling, garnering massive investment and media attention. Ranging from monoclonal antibodies to engineered T-cells, companies are rapidly learning how to harness the power of the immune system to fight...
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
